|
|
|
|
||
DVAX and IDRA - ImmunoncologyIt appears that the two companies are splitting the cancer drug market avoiding competition. IDRA (mostly) focused on anti pd1 refractory patients, using combination with other (than anti pd1) inhibitors. and DVAX mostly focused on first and second line combination with anti pd1 in naive patients. They have similar drugs (TLR 9 agonists) and avoiding competition may be a very clever way to segmnent the market and get more value out of their drugs. Thoughts? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
874 | Re: DVAX and IDRA - Immunoncology | raferjack | 3 | 1/20/2018 1:51:27 PM |
878 | Re: DVAX and IDRA - Immunoncology | cert77 | 0 | 1/20/2018 10:01:04 PM |